trazodone has been researched along with Parkinsonian Disorders in 4 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trazodone was discontinued, and his symptoms resolved within a week." | 1.72 | Trazodone-induced parkinsonism: A case report. ( Colangelo, T; Mills, A; Sharma, KD, 2022) |
| "Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson's disease (PD)." | 1.48 | Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. ( Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, KD | 1 |
| Colangelo, T | 1 |
| Mills, A | 1 |
| Hamadjida, A | 1 |
| Nuara, SG | 1 |
| Gourdon, JC | 1 |
| Huot, P | 1 |
| Le Ber, I | 1 |
| Dubois, B | 1 |
| Fukunishi, I | 1 |
| Kitaoka, T | 1 |
| Shirai, T | 1 |
| Kino, K | 1 |
| Kanematsu, E | 1 |
| Sato, Y | 1 |
1 review available for trazodone and Parkinsonian Disorders
| Article | Year |
|---|---|
[Frontotemporal dementia].
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alzheimer Disease; Amyotrophic Lateral Sclerosis | 2007 |
3 other studies available for trazodone and Parkinsonian Disorders
| Article | Year |
|---|---|
Trazodone-induced parkinsonism: A case report.
Topics: Activities of Daily Living; Aged; Depressive Disorder, Major; Humans; Male; Parkinsonian Disorders; | 2022 |
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Exce | 2018 |
A hemodialysis patient with trazodone-induced parkinsonism.
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Kidney Failure, Chronic; Male; Middle | 2002 |